Live News

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use

Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improv...

Best Practice & Research Clinical Haematology

0 0

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential

Chimeric antigen receptor T (CAR-T) cell therapy is a form adoptive T cell therapy where host T cells are transduced with ...

Best Practice & Research Clinical Haematology

0 0

Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases

Mesenchymal stromal cells (MSCs) have been primarily used in regenerative medicine as a cell-based therapy due to their un...

Best Practice & Research Clinical Haematology

0 0

Cytokines in hematology, hematopoietic cell transplantation and immune effector cell therapy: Preface

Best Practice & Research Clinical Haematology

0 0

Endogenous and exogenous cytokines: An overview and introduction

Cytokines are small proteins, secreted by many cells, including but not limited to immune cells such as lymphocytes and ma...

Best Practice & Research Clinical Haematology

0 0

Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)

Since their initial introduction into clinical practice, immune checkpoint inhibitors (ICIs) that target the cytotoxic T-l...

Best Practice & Research Clinical Haematology

0 0

Cytokines and immune effector cell therapy

Immune effector cell (IEC) therapy has revolutionized the treatment landscape of hematologic malignancies with ongoing eff...

Best Practice & Research Clinical Haematology

0 0

Cytokines in transplantation tolerance

A major challenge in the current practice of transplantation is the requirement for long term immunosuppression to prevent...

Best Practice & Research Clinical Haematology

0 0

Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions

Hematologic diseases have seen significant therapeutic advancements in recent years, particularly through the development ...

Best Practice & Research Clinical Haematology

0 0

Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma

Multiple myeloma (MM), characterized by an abnormal proliferation of plasma cells, accounts for 10 %–15 % of hematological...

Best Practice & Research Clinical Haematology

0 0

CAR-NK cells for haematological cancers

Cell therapy has developed rapidly. Chimeric antigen receptor-T (CAR-T)-cell therapy re-shaped therapy of many B-cell canc...

Best Practice & Research Clinical Haematology

0 0

Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse

Lulu Kong: Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, ...

Best Practice & Research Clinical Haematology

0 0

Tumor microenvironment in CAR-T cell therapy for lymphoma

Recent advances in chimeric antigen receptor (CAR)-T cell therapy have revolutionized the therapeutic landscape for relaps...

Best Practice & Research Clinical Haematology

0 0

Natural born Killers: Harnessing NK cells to treat cancer

Natural killer (NK) cells were first described in the 1970s for their ability to destroy tumor cells without prior sensiti...

Best Practice & Research Clinical Haematology

0 0

Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology

In this issue of Best Practice & Research Clinical Haematology, the focus is on mesenchymal stromal cells (MSC), begin...

Best Practice & Research Clinical Haematology

0 0

Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception

Plasma cell dyscrasias (PCDs) includes a heterogenous group of disorders characterized by clonal proliferation of aberrant...

Best Practice & Research Clinical Haematology

0 0

Bispecific T-cell engager therapy for multiple myeloma

With upfront use of triplet- and quadruplet-based regimens coupled with autologous stem cell transplant (ASCT) and mainten...

Best Practice & Research Clinical Haematology

0 0

Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]

Volume 38, Issue 3, September 2025, 101648Author links open overlay panelMatthew J. Hadfield a 1, Ross D. Merkin b 1, Sher...

Best Practice & Research Clinical Haematology

0 0

Advances in NK cell therapy for multiple myeloma

Multiple myeloma (MM) is a hematologic malignancy involving plasma cells, accounting for about 10 % of hematologic maligna...

Best Practice & Research Clinical Haematology

0 0

Adoptive cellular therapies in non-Hodgkin lymphomas

Volume 38, Issue 3, September 2025, 101637Author links open overlay panel, , , , , , , , , , , , , , , , AbstractLymphomas...

Best Practice & Research Clinical Haematology

0 0

Adoptive cellular therapies in multiple myeloma

Volume 38, Issue 3, September 2025, 101638Author links open overlay panel, , , , , , , , , , , , , AbstractPlasma cell mye...

Best Practice & Research Clinical Haematology

0 0

Immune therapy of haematological cancers

Best Practice & Research Clinical Haematology

0 0

Special issue 37.3: “Genetics and function of HLA and immune-related genes in hematopoietic cell transplantation and cellular immunotherapy”